- Fellowship - Parkland Health & Hospital System (1970-1971), Endocrinology & Metabolism
- Residency - University of Pittsburgh Medical Center Montefiore/Presbyterian (1967-1968), Internal Medicine
- Internship - University of Pittsburgh Medical Center Montefiore/Presbyterian (1966-1967), Internal Medicine
- Medical School - University of Pittsburgh School of Medicine
Philip Raskin, M.D.
- Clifton and Betsy Robinson Chair in Biomedical Research
- Internal Medicine - Endocrinology
Dr. Raskin is the holder of the Clifton and Betsy Robinson Chair in Biomedical Research.
After receiving his medical degree from the University of Pittsburgh School of Medicine, Dr. Raskin stayed there to complete his residency in internal medicine. He then performed a fellowship in endocrinology, diabetes, and metabolism at UT Southwestern.
Currently, Dr. Raskin is the Director of the Diabetes Clinic at Parkland Hospital. He is the Principal Investigator in four NIH-funded multicenter diabetes trials: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), TrialNet, The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study), and Vitamin D to Prevent Type 2 Diabetes (D2d Study).
He was the editor of the Journal of Diabetes and Its Complications from 1990 to 2011 and is also a past editor of Clinical Diabetes.
Dr. Raskin is widely published in peer-reviewed journals including the New England Journal of Medicine, The Journal of Clinical Investigation, Diabetes, Diabetes Care, the Annals of Internal Medicine, and the Journal of Diabetes and Its Complications. He also has authored numerous chapters in clinical textbooks.
Meet Dr. Raskin
Philip Raskin, M.D., a board-certified endocrinologist, focuses his practice solely on diabetes, making him one of the most sought-after diabetes specialists in Dallas.
A Texas Monthly Super Doctor for seven straight years and a D Magazine Best Doctor for three, Dr. Raskin’s main goal is to give his patients good advice that they can and will use. After all, most diabetes management happens outside the doctor’s office.
“I choose therapies that I think will work for each patient. I teach him or her what to do and try to help each patient understand how to make adjustments when things change,” Dr. Raskin says.
“Because the patients are the ones at home checking their levels and giving themselves shots, I try to set them up for success by offering useful advice.”
In addition to care from physicians like Dr. Raskin, UT Southwestern offers a Diabetes Management Program in English and Spanish to help patients gain a clearer understanding of diabetes and how to control it. When diabetes goes unmanaged, the consequences can be severe, including blindness, kidney damage, heart disease, stroke, and amputations.
Dr. Raskin chose to focus his career on diabetes because it’s treatable.
“I can really help people with diabetes and watch them live a long, healthy life,” he says. “It takes a lot of care and attention on their part, but people who are willing to put in the effort can do well.”
In addition to taking care of patients, Dr. Raskin is a clinical researcher widely renowned for his work in diabetes, diabetes complications, and diabetes management.
- Fellow American College of Physicians,
- Fellow American College of Endocrinology,
- Endocrine Society
- American Society of Clinical Investigation,
- American Diabetes Association
- The Best Doctors In American, 1992-1993, 1994-1995, 2001-2002, 2005-2006
- Owens Fellowship University of Pittsburgh
- Alpha Omega Alpha
Independence of cholesterol and fatty acid biosynthesis from cyclic AMP concentration in the perfused rat liver.
Raskin P, McGarry JD, Foster DW J. Biological Chemistry 1974 249 6029
Increased erythrocyte aldosed reductase activity in type 1 diabetic patients
Hamada Y, Kito R, and Raskin P Diabetic Medicine 1991 8 226-231
Lung function changes related to diabetes mellitus
C W Hsia, P Raskin Diabetes Technology & Therapeutics 2007 9(1) S73-S82
Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues
M Brod, D Cobden, M Lammert, D Bushnell, P Raskin Health and Quality of Life Outcomes 2007 5 8
Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted
I Lingvay, P F Kaloyanova, B Adams-Huet, P Raskin Journal of Investigative Medicine 2007 55(2) 62-68
Weight gain in type 2 diabetes mellitus
A N Jacob, K Salinas, B Adams-Huet, P Raskin Diabetes, Obesity and Metabolism 2007 9 386-393
Effects of multiple daily insulin injections on peripheral glucose disposal in Latin Americans with type 2 diabetes mellitus
L Aviles-Santa, K Salinas, B Adams-Huet, P Raskin Journal if Investigative Medicine January 2007 55(1) 11-17
Basal insulin or premix analogue therapy in type 2 diabetes patients
P Raskin, P A Hollander, A Lewin, R A Gabbay, B Bopde, B Garber, INITIATE Study Group European Journal of Internal Medicine January 2007 18 56-62
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US
J A Ray, W J Valentine, S Roze, L Nicklasson, D Cobden, P Raskin, A Garber, A J Palmer Diabetes, Obesity, and Metabolism January 2007 9(1) 103-113
Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes
I Lingvay, P Raskin, L S Szezepaniak Journal of Diabetes and Its Complications May 2007 21(3) 137-142
- Independence of cholesterol and fatty acid biosynthesis from cyclic AMP concentration in the perfused rat liver.
- New diabetes therapies
- Lipid Disorders
- Diabetic Complications
Q&A by Dr. Raskin
Results: 1 Locations